



## News Release

### **MEDGENICS TO PRESENT AT THE 10<sup>TH</sup> ANNUAL ILSI BIOMED 2011 CONFERENCE**

**MISGAV, Israel and VIENNA, Va. (May 19, 2011) – Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG)** today announced that Andrew L. Pearlman, Ph.D., the Company's President and CEO, will present a corporate overview at the 10<sup>th</sup> Annual Israeli Life Sciences Industry Biomed 2011 Conference taking place at the David Intercontinental & Dan Panorama Hotels in Tel Aviv, Israel from May 23-25, 2011. Dr. Pearlman will deliver the Company's presentation on Monday, May 23 at 4:30 p.m. (local time) in Hall B.

ILSI-Biomed 2011 follows the success of its previous annual conferences: last year's event drew 6,000 industry professionals, engineers and scientists, with 1,000 participants from 42 countries and more than 2,500 one-on-one meetings. This provides Medgenics with significant opportunity to showcase before a global audience of relevant industry leaders its novel, tissue-based technology platform, the Biopump, for the sustained production and dosing of therapeutic proteins using a patient's own tissue.

#### **About Israeli Life Sciences Industry**

The Israel Life Science Industry (ILSI) is composed of medical device, biotechnology, pharmaceutical and medical service companies, universities and private research institutions, and providers of services to the industry such as venture capitalists, lawyers, accountants and incubators. The goal of ILSI is to develop solid information about the medical research and manufacturing community in Israel, and to make that information available to political leaders, the news media, venture capitalists, investment bankers, and the public. It is exactly this information required by potential investors be it strategic corporate players or financial investors worldwide. The intent is to demonstrate that medical research and manufacturing is a major contributor to Israel's economy - with unusually great potential for financial growth and job creation.

#### **About Medgenics**

Medgenics is developing and commercializing Biopump, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis C and hemophilia. Medgenics believes this approach has multiple benefits compared with current treatments, which include regular and costly injections of therapeutic proteins.

Medgenics has three long-acting protein therapy products in development based on this technology:

- EPODURE (now completing a Phase I/II dose-ranging trial) to produce and deliver erythropoietin for many months from a single administration, has demonstrated elevation and stabilization of hemoglobin levels in anemic patients for 6-28 months;
- INFRADURE (to commence a Phase I/II trial in Israel in 2011) to produce a sustained therapeutic dose of interferon-alpha for use in the treatment hepatitis C;
- HEMODURE is a sustained Factor VIII therapy for the prophylactic treatment of hemophilia, now in development in collaboration with Medgenics' first major pharmaceutical partner, a market leader in hemophilia.

Medgenics intends to develop its innovative products and bring them to market via strategic partnerships with major pharmaceutical and/or medical device companies. In addition to treatments for anemia, hepatitis C and hemophilia, Medgenics plans to develop and/or out-license a pipeline of future Biopump products targeting the large and rapidly growing global protein therapy market, which is forecast to reach \$132 billion in 2013. Other potential applications for Biopumps include multiple sclerosis, arthritis, pediatric growth hormone deficiency, obesity and diabetes.

### **Forward-looking Statements**

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.

### **For further information, contact:**

Medgenics, Inc.  
Dr. Andrew L. Pearlman

Phone: +972 4 902 8900

Lippert/Heilshorn & Associates, Inc.  
Anne Marie Fields  
afields@lhai.com

Phone: 212-383-3777

De Facto Communications  
Mike Wort  
Anna Dunphy

Phone: +44 207 861 3838

Religare Capital Markets (Nomad)  
James Pinner

Phone: +44 207 444 0800

Derek Crowhurst

SVS Securities plc (Joint Broker)  
Alex Matthey  
Ian Callaway

Phone: +44 207 638 5600

Nomura Code Securities (Joint Broker)  
Jonathan Senior

Phone: +44 207 776 1219

###